Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Bortezomib is active in mantle cell lymphoma (MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase II study to evaluate the safety an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Till, Brian G., Li, Hongli, Bernstein, Steven H., Fisher, Richard I., Burack, W. Richard, Rimsza, Lisa M., Floyd, Justin D., DaSilva, Marco A., Moore, Dennis F., Pozdnyakova, Olga, Smith, Sonali M., LeBlanc, Michael, Friedberg, Jonathan W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4710555/
https://ncbi.nlm.nih.gov/pubmed/26492567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13818
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados